The global oral contrast agent market is anticipated to grow at a significant CAGR 4.8% during the forecast period (2022-2028). Oral contrast agents are barium- or iodine-based. They are used for bowel opacification. Additionally, the concentration of barium determines if it enhances the diagnosis or causes an artifact and obscures pathology. The major factor driving the demand for oral contrast agent is the new product launches and drug approvals across the globe. 

For instance, in December 2021, Bayer announced the approval of two pediatric indications Xarelto (rivaroxaban) from the US Food and Drug Administration (FDA). It is used for the treatment of venous thromboembolism (VTE) and to reduce the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral anticoagulant treatment and thromboprophylaxis in children aged two years and older with congenital heart disease who have undergone the Fontan procedure. Additionally, in December 2021, Ascelia Pharma AB presented a study in which Orviglance was compared against a gadolinium-based contrast agent at RSNA 2021. Orviglance is a novel manganese-based oral contrast agent for magnetic resonance imaging (MRI). 

Some major players in the market include General Electric Co., Bracco Imaging SpA, and Bayer AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2021, Ascelia Pharma AB announced the acceptance of the Investigational New Drug (IND) application for the upcoming global Phase 2 clinical study in gastric cancer with the daily oral chemotherapy candidate drug Oncoral from the US Food and Drug Administration (FDA).

Market Coverage

• The market number available for – 2021-2028

• Base year- 2021

• Forecast period- 2022-2028

• Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- General Electric Co., Bracco Imaging SpA, and Bayer AG, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Oral Contrast Agent Market Report by Segment

By Type

• Barium-based Contrast Media

• Iodinated Contrast Media

• Gadolinium-based Contrast Media

• Microbubble Contrast Media

By Application 

• CVD

• Cancer

• Gastrointestinal Disorders

• Musculoskeletal Disorders

• Neurological Disorders

• Nephrological Disorders

Global Oral Contrast Agent Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa